SCHEMBL25217936

SCHEMBL25217936

COc1ccc(/C=C/C(=O)c2ccc(O)cc2)cc1COc1c(C)cccc1C

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.71
▸ KMT2A Q03164 7/20 0.71
▸ MAPT P10636 6/20 0.71
▸ ALDH1A1 P00352 4/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.71
▸ POLB P06746 1/20 0.71
▸ LMNA P02545 5/20 0.68
▸ KDM4E B2RXH2 2/20 0.68
▸ THRB P10828 1/20 0.60
▸ RECQL P46063 1/20 0.59
▸ CTSL P07711 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ ABCG2 Q9UNQ0 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ HTT P42858 1/20 0.53
▸ NR1H4 Q96RI1 1/20 0.53
▸ ABCB1 P08183 1/20 0.51
▸ CAPN1 P07384 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30382606 1.00 MEN1 (0.71) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL30382969 0.90 MAPT (0.72) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25279687 0.90 MAPT (0.72) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25201205 0.90 MAPT (0.72) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25217693 0.89 RECQL (0.74) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL30384712 0.88 MEN1 (0.67) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25212438 0.88 MEN1 (0.67) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25190969 0.87 CYP19A1 (0.66) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25198208 0.86 MEN1 (0.76) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL25199678 0.86 MEN1 (0.69) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885MAPT 3297/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885MAPT 3512/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885MAPT 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback